Positive End of Phase 2 discussion with FDA, including alignment on Phase 3 design Bayley-4 expressive communication selected as Phase 3 study primary endpoint Initiation of ION582 Phase 3 study planned for H1 2025 Ionis […]
Tag: Ionis Pharmaceuticals
Ionis to hold third quarter 2024 financial results webcast
Webcast scheduled for Wednesday, November 6 at 11:30 a.m. Eastern Time CARLSBAD, Calif., Oct. 23, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, November […]
